GALE - Galena Biopharma, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.30
+0.00 (+1.35%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close0.30
Open0.30
Bid0.28 x 4000
Ask0.42 x 900
Day's range0.29 - 0.31
52-week range0.26 - 4.75
Volume528,165
Avg. volume612,285
Market cap13.71M
Beta2.33
PE ratio (TTM)N/A
EPS (TTM)-1.52
Earnings date7 Aug 2017 - 11 Aug 2017
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.00
Trade prices are not sourced from all markets
  • Associated Press10 days ago

    Galena Biopharma reports 3Q loss

    On a per-share basis, the San Ramon, California-based company said it had a loss of 15 cents. In the final minutes of trading on Thursday, the company's shares hit 31 cents. A year ago, they were trading ...

  • GlobeNewswire11 days ago

    Galena Biopharma Reports Third Quarter 2017 Financial Results

    SAN RAMON, Calif., Nov. 09, 2017-- Galena Biopharma, Inc., a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs, today reported its financial results ...

  • PR Newswire20 days ago

    SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Galena Biopharma, Inc. - GALE

    NEW YORK , Oct. 31, 2017 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York ...

  • PR Newswire2 months ago

    SELLAS Enters into a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Kenilworth, N.J., USA

    HAMILTON, Bermuda and NEW YORK, Oct. 2, 2017 /PRNewswire/ -- SELLAS Life Sciences Group, Ltd. (SELLAS), a development-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced entry into a Clinical Trial Collaboration and Supply Agreement for the conduct of a combination clinical trial targeting multiple cancer types with Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada).  SELLAS' Wilms tumor-1 (WT1)-targeting peptide immunotherapeutic agent, galinpepimut-S, will be administered in combination with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a Phase 1/2 trial enrolling patients in five cancer indications, including both hematologic malignancies and solid tumors.

  • PR Newswire2 months ago

    SELLAS Enters into a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Kenilworth, N.J., USA

    HAMILTON, Bermuda and NEW YORK, Oct. 2, 2017 /PRNewswire/ --  SELLAS Life Sciences Group, Ltd. (SELLAS), a development-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced entry into a Clinical Trial Collaboration and Supply Agreement for the conduct of a combination clinical trial targeting multiple cancer types with Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada).  SELLAS' Wilms tumor-1 (WT1)-targeting peptide immunotherapeutic agent, galinpepimut-S, will be administered in combination with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a Phase 1/2 trial enrolling patients in five cancer indications, including both hematologic malignancies and solid tumors.

  • Associated Press3 months ago

    Galena Biopharma reports 2Q loss

    The San Ramon, California-based company said it had a loss of 22 cents per share. Losses, adjusted to account for discontinued operations and non-recurring costs, were 16 cents per share. In the final ...

  • Associated Press6 months ago

    Galena Biopharma reports 1Q loss

    On a per-share basis, the San Ramon, California-based company said it had a loss of 45 cents. Losses, adjusted to account for discontinued operations, came to 9 cents per share. In the final minutes of ...

  • Associated Press8 months ago

    Galena Biopharma reports 4Q loss

    The San Ramon, California-based company said it had a loss of 49 cents per share. Losses, adjusted for non-recurring gains, came to 58 cents per share. For the year, the company reported that its loss ...